AU3613995A - Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases - Google Patents

Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Info

Publication number
AU3613995A
AU3613995A AU36139/95A AU3613995A AU3613995A AU 3613995 A AU3613995 A AU 3613995A AU 36139/95 A AU36139/95 A AU 36139/95A AU 3613995 A AU3613995 A AU 3613995A AU 3613995 A AU3613995 A AU 3613995A
Authority
AU
Australia
Prior art keywords
cyclooxygenase
inhibitors
treatment
neurodegenerative diseases
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU36139/95A
Other versions
AU715676B2 (en
Inventor
Yves Ducharme
Jacques Yves Gauthier
Raymond George Hill
Yves Leblanc
Serge Leger
Petpiboon Prasit
Dalip Jaicaran Sastri Sirinathsinghji
Michel Therien
Zhaoyin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Organon Pharma UK Ltd
Original Assignee
Merck Frosst Canada and Co
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU61788/94A external-priority patent/AU6178894A/en
Priority claimed from GB9420616A external-priority patent/GB9420616D0/en
Application filed by Merck Frosst Canada and Co, Merck Sharp and Dohme Ltd filed Critical Merck Frosst Canada and Co
Priority to AU36139/95A priority Critical patent/AU715676B2/en
Publication of AU3613995A publication Critical patent/AU3613995A/en
Assigned to MERCK FROSST CANADA & CO., MERCK SHARP & DOHME LIMITED reassignment MERCK FROSST CANADA & CO. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK FROSST CANADA INC., MERCK SHARP & DOHME LIMITED
Application granted granted Critical
Publication of AU715676B2 publication Critical patent/AU715676B2/en
Anticipated expiration legal-status Critical
Withdrawn - After Issue legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU36139/95A 1993-03-12 1995-10-09 Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases Withdrawn - After Issue AU715676B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36139/95A AU715676B2 (en) 1993-03-12 1995-10-09 Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US030924 1993-03-12
AU61788/94A AU6178894A (en) 1993-03-12 1994-03-10 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
GB9420616A GB9420616D0 (en) 1994-10-12 1994-10-12 Method, compositions and use
PCT/GB1995/002382 WO1996011676A1 (en) 1994-10-12 1995-10-09 Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU36139/95A AU715676B2 (en) 1993-03-12 1995-10-09 Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU61788/94A Division AU6178894A (en) 1993-03-12 1994-03-10 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU27746/02A Division AU2774602A (en) 1993-03-12 2002-03-27 Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU3613995A true AU3613995A (en) 1996-05-06
AU715676B2 AU715676B2 (en) 2000-02-10

Family

ID=25633272

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36139/95A Withdrawn - After Issue AU715676B2 (en) 1993-03-12 1995-10-09 Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Country Status (1)

Country Link
AU (1) AU715676B2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2180651A1 (en) * 1994-01-10 1995-07-13 Yves Ducharme Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
AU715676B2 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
AU6566094A (en) Heterocyclic derivatives in the treatment of ischaemia and related diseases
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU8154294A (en) Methods of inhibiting atrophy of the skin and vagina
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU6801694A (en) The treatment of small animals
AU4098393A (en) Laminate and use of the same
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
AU678616B2 (en) Novel spirooxazines and use thereof in the field of ophthalmic optics
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
AU7384094A (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
AU2807492A (en) Use of misoprostol for the treatment of allergy
AU9226198A (en) The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury
IL115505A0 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU4787593A (en) Heterocyclic derivatives useful in the treatment of cardiovascular diseases
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU1870292A (en) Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
AU4812393A (en) Use of rapamycin in the treatment of aids
AU2663300A (en) Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances
AU5371694A (en) Use of the tarchonanthus camphoratus
AU6491890A (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
AU3963093A (en) Improvements in the herbicidal treatment of plants
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: ADD INVENTORS RAYMOND GEORGE HILL AND DALIP JAICARAN SASTRI SIRINATHSINGHJI

CB Opposition lodged by

Opponent name: PHARMACIA CORPORATION

MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal
CFC Application withdrawn - opposition proceedings

Opponent name: PHARMACIA CORPORATION